Suppl. Fig. 3. ARN-509 causes tumor regression in LNCaP/AR-luc xenograft models of castration-resistant prostate cancer. Castrate male mice bearing LNCaP/AR-luc tumors >100 mm³ were treated for 21 days by oral daily gavage with vehicle or antiandrogen. The percent change in volume for individual tumors (11-12 tumors per treatment group) after 21 days is represented as a waterfall plot (y axis, left). p = 0.0001 as determined by Kruskall-Wallis non-parametric one-way Anova test, with p < 0.05 for: Vehicle versus 10 mg/kg ARN-509; 10 mg/kg Bic versus 10 mg/kg ARN-509, using Dunn’s multiple comparison post-test. Plasma concentrations of bicalutamide and ARN-509 for each mouse were measured 20 hours after the final dose on day 28 (filled circles above the waterfall plot; y axis, right).